Probiotics and their role in gastrointestinal cancers prevention and treatment: An overview

Ahmad Javanmard, Sara Ashtari, Babak Sabet, Seyed Hossein Davoodi, Mohammad Rostami-Nejad, Mohammad Esmail Akbari, Azadeh Niaz, Amir Mohammad Mortazavian

Abstract


39

 

Cancers of the gastrointestinal (GI) track are a serious global health problem. The human GI tract is home to trillions of
microorganisms that known as gut microbiota and have established a symbiotic relationship with the host. The human intestinal
microbiota plays an important role in the development of the gut immune system, metabolism, nutrition absorption, production of
short-chain fatty acids and essential vitamins, resistance to pathogenic microorganisms, and modulates a normal immunological
response. Microbiota imbalance has been involved in many disorders including inflammatory bowel disease, obesity, asthma,
psychiatric illnesses, and cancers. Oral administration of probiotics seems to play a protective role against cancer development as a
kind of functional foods. Moreover, clinical application of probiotics has shown that some probiotic strains can reduce the incidence
of post-operative inflammation in cancer patients. In the present narrative review, we carried out update knowledge on probiotic
effects and underlying mechanism to GI cancers. Currently, it is accept that most commercial probiotic products are generally safe
and can used as a supplement for cancer prevention and treatment. Nevertheless, well-designed, randomized, double blind, placebocontrolled
human studies are required to gain the acceptance of the potential probiotics as an alternative therapy for cancer control..
Keywords: Probiotic, Prebiotics, Gastrointestinal cancer, Gut microbiota.
(Please cite as: Javanmard A, Ashtari S, Sabet B, Davoodi SH, Rostami-Nejad M, Akbari ME, et al. Probiotics and
their role in gastrointestinal cancers prevention and treatment; an overview. Gastroenterol Hepatol Bed Bench
2018;11(4):284-295).


Keywords


probiotic, prebiotics, gastrointestinal cancer, gut microbiota

Full Text:

PDF - View Count=7

References


Indian Council of Medical Research Task F, Co-ordinating Unit I, Co-ordinating Unit DBT. ICMR-DBT guidelines for evaluation of probiotics in food. The Indian journal of medical research 2011;134:22-5.

Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, et al. Recommendations for probiotic use-2011 update. Journal of clinical gastroenterology 2011;45 Suppl:S168-71.

Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS microbiology reviews 2004;28(4):405-40.

Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nature reviews Microbiology 2005;3(10):777-88.

Russo F, Linsalata M, Orlando A. Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World journal of gastroenterology 2014;20(37):13258-72.

Rasouli BS, Ghadimi-Darsajini A, Nekouian R, Iragian GR. In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression. Journal of cancer research and therapeutics 2017;13(2):246-51.

Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. Experimental and therapeutic medicine 2016;12(1):3-17.

Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery - a double-blind study. Alimentary pharmacology & therapeutics 2011;33(1):50-63.

Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, et al. An update on the use and investigation of probiotics in health and disease. Gut 2013;62(5):787-96.

Holzapfel WH, Haberer P, Geisen R, Bjorkroth J, Schillinger U. Taxonomy and important features of probiotic microorganisms in food and nutrition. The American journal of clinical nutrition 2001;73(2 Suppl):365s-73s.

Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Current opinion in biotechnology 2006;17(2):204-10.

Nissle A. [Explanations of the significance of colonic dysbacteria & the mechanism of action of E. coli therapy (mutaflor)]. Die Medizinische 1959;4(21):1017-22.

Mollenbrink M, Bruckschen E. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Medizinische Klinik (Munich, Germany : 1983) 1994;89(11):587-93.

Schutz E. The treatment of intestinal diseases with Mutaflor. A multicenter retrospective study. Fortschritte der Medizin 1989;107(28):599-602.

Felis GE, Dellaglio F. Taxonomy of Lactobacilli and Bifidobacteria. Current issues in intestinal microbiology 2007;8(2):44-61.

Anadon A, Martinez-Larranaga MR, Aranzazu Martinez M. Probiotics for animal nutrition in the European Union. Regulation and safety assessment. Regulatory toxicology and pharmacology : RTP 2006;45(1):91-5.

Gaggia F, Mattarelli P, Biavati B. Probiotics and prebiotics in animal feeding for safe food production. International journal of food microbiology 2010;141 Suppl 1:S15-28.

Markowiak P, Slizewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017;9(9).

Di Cerbo A, Palmieri B. Review: The market of probiotics. Pakistan journal of pharmaceutical sciences 2015;28(6):2199-206.

Orlando A, Russo F. Intestinal microbiota, probiotics and human gastrointestinal cancers. Journal of gastrointestinal cancer 2013;44(2):121-31.

Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterology and hepatology from bed to bench 2015;8(1):19-27.

Ghoncheh M, Salehiniya H. Inequality in the Incidence and Mortality of All Cancers in the World. Iranian journal of public health 2016;45(12):1675-7.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014 Available from: http://globocan.iarc.fr, accessed on 16/01/2015.

Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer letters 2014;345(2):258-70.

Zhang MM, Cheng JQ, Xia L, Lu YR, Wu XT. Monitoring intestinal microbiota profile: a promising method for the ultraearly detection of colorectal cancer. Medical hypotheses 2011;76(5):670-2.

Zuccotti GV, Meneghin F, Raimondi C, Dilillo D, Agostoni C, Riva E, et al. Probiotics in clinical practice: an overview. The Journal of international medical research 2008;36 Suppl 1:1a-53a.

De Preter V, Hamer HM, Windey K, Verbeke K. The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health? Molecular nutrition & food research 2011;55(1):46-57.

Kumar M, Kumar A, Nagpal R, Mohania D, Behare P, Verma V, et al. Cancer-preventing attributes of probiotics: an update. International journal of food sciences and nutrition 2010;61(5):473-96.

Liong MT. Roles of probiotics and prebiotics in colon cancer prevention: Postulated mechanisms and in-vivo evidence. International journal of molecular sciences 2008;9(5):854-63.

Rafter J. The effects of probiotics on colon cancer development. Nutrition research reviews 2004;17(2):277-84.

Lee JW, Shin JG, Kim EH, Kang HE, Yim IB, Kim JY, et al. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. Journal of veterinary science 2004;5(1):41-8.

Baldwin C, Millette M, Oth D, Ruiz MT, Luquet FM, Lacroix M. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutrition and cancer 2010;62(3):371-8.

Russo F, Orlando A, Linsalata M, Cavallini A, Messa C. Effects of Lactobacillus rhamnosus GG on the cell growth and polyamine metabolism in HGC-27 human gastric cancer cells. Nutrition and cancer 2007;59(1):106-14.

Orlando A, Messa C, Linsalata M, Cavallini A, Russo F. Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacology and immunotoxicology 2009;31(1):108-16.

Orlando A, Refolo MG, Messa C, Amati L, Lavermicocca P, Guerra V, et al. Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2.1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines. Nutrition and cancer 2012;64(7):1103-11.

Kim Y, Lee D, Kim D, Cho J, Yang J, Chung M, et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Archives of pharmacal research 2008;31(4):468-73.

Ma EL, Choi YJ, Choi J, Pothoulakis C, Rhee SH, Im E. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. International journal of cancer 2010;127(4):780-90.

Kim Y, Oh S, Yun HS, Oh S, Kim SH. Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Letters in applied microbiology 2010;51(2):123-30.

Borowicki A, Michelmann A, Stein K, Scharlau D, Scheu K, Obst U, et al. Fermented wheat aleurone enriched with probiotic strains LGG and Bb12 modulates markers of tumor progression in human colon cells. Nutrition and cancer 2011;63(1):151-60.

Stein K, Borowicki A, Scharlau D, Schettler A, Scheu K, Obst U, et al. Effects of synbiotic fermentation products on primary chemoprevention in human colon cells. The Journal of nutritional biochemistry 2012;23(7):777-84.

Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel MT, Corcos L, Jan G. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PloS one 2012;7(3):e31892.

Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2017;65(2):311-5.

So SS, Wan ML, El-Nezami H. Probiotics-mediated suppression of cancer. Current opinion in oncology 2017;29(1):62-72.

Hatakka K, Holma R, El-Nezami H, Suomalainen T, Kuisma M, Saxelin M, et al. The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. International journal of food microbiology 2008;128(2):406-10.

Worthley DL, Le Leu RK, Whitehall VL, Conlon M, Christophersen C, Belobrajdic D, et al. A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. The American journal of clinical nutrition 2009;90(3):578-86.

Ohara T, Yoshino K, Kitajima M. Possibility of preventing colorectal carcinogenesis with probiotics. Hepato-gastroenterology 2010;57(104):1411-5.

Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G, et al. A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. World journal of surgery 2015;39(11):2776-83.

Aisu N, Tanimura S, Yamashita Y, Yamashita K, Maki K, Yoshida Y, et al. Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer. Experimental and therapeutic medicine 2015;10(3):966-72.

Yang Y, Xia Y, Chen H, Hong L, Feng J, Yang J, et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget 2016;7(7):8432-40.

Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. British journal of cancer 2007;97(8):1028-34.

Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, et al. Use of probiotics for prevention of radiation-induced diarrhea. World journal of gastroenterology 2007;13(6):912-5.

Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Alimentary pharmacology & therapeutics 2014;40(5):409-21.

Nam YD, Kim HJ, Seo JG, Kang SW, Bae JW. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PloS one 2013;8(12):e82659.

Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. International journal of cancer 2009;125(3):666-73.

Bhandari A, Crowe SE. Helicobacter pylori in gastric malignancies. Current gastroenterology reports 2012;14(6):489-96.

Salama NR, Hartung ML, Muller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nature reviews Microbiology 2013;11(6):385-99.

Ashtari S, Pourhoseingholi MA, Molaei M, Taslimi H, Zali MR. The prevalence of Helicobacter pylori is decreasing in Iranian patients. Gastroenterology and hepatology from bed to bench 2015;8(Suppl 1):S23-9.

Zhu XY, Liu F. Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy. 2017;18(4):195-202.

Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Alimentary pharmacology & therapeutics 2007;25(2):155-68.

Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World journal of gastroenterology 2018;24(1):139-49.

Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World journal of gastroenterology 2014;20(47):18013-21.

Gisbert JP, Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Alimentary pharmacology & therapeutics 2011;34(9):1047-62.

Kokkola A, Valle J, Haapiainen R, Sipponen P, Kivilaakso E, Puolakkainen P. Helicobacter pylori infection in young patients with gastric carcinoma. Scandinavian journal of gastroenterology 1996;31(7):643-7.

Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World journal of gastroenterology 2012;18(43):6302-7.

Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in GLOBACON 2012. Gastroenterology and hepatology from bed to bench 2017;10(4):245-57.

Olah A, Belagyi T, Poto L, Romics L, Jr., Bengmark S. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepato-gastroenterology 2007;54(74):590-4.

Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. The British journal of surgery 2002;89(9):1103-7.

Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 2008;371(9613):651-9.

Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Critical care 2014;18(2):R57.

De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology (Baltimore, Md) 2014;59(5):1738-49.

Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PloS one 2013;8(4):e62885.

Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499(7456):97-101.

Li J, Sung CY, Lee N, Ni Y, Pihlajamaki J, Panagiotou G, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proceedings of the National Academy of Sciences of the United States of America 2016;113(9):E1306-15.

Kasmi G, Andoni R, Mano V, Kraja D, Muco E, Kasmi I. Streptococcus bovis isolated in haemoculture a signal of malignant lesion of the colon. Clinical laboratory 2011;57(11-12):1007-9.

Nakamura J, Kubota Y, Miyaoka M, Saitoh T, Mizuno F, Benno Y. Comparison of four microbial enzymes in Clostridia and Bacteroides isolated from human feces. Microbiology and immunology 2002;46(7):487-90.

Strofilas A, Lagoudianakis EE, Seretis C, Pappas A, Koronakis N, Keramidaris D, et al. Association of helicobacter pylori infection and colon cancer. Journal of clinical medicine research 2012;4(3):172-6.

Chang JH, Shim YY, Cha SK, Reaney MJ, Chee KM. Effect of Lactobacillus acidophilus KFRI342 on the development of chemically induced precancerous growths in the rat colon. Journal of medical microbiology 2012;61(Pt 3):361-8.

Foo NP, Ou Yang H, Chiu HH, Chan HY, Liao CC, Yu CK, et al. Probiotics prevent the development of 1,2-dimethylhydrazine (DMH)-induced colonic tumorigenesis through suppressed colonic mucosa cellular proliferation and increased stimulation of macrophages. Journal of agricultural and food chemistry 2011;59(24):13337-45.

De Vuyst L, Leroy F. Bacteriocins from lactic acid bacteria: production, purification, and food applications. Journal of molecular microbiology and biotechnology 2007;13(4):194-9.

Lievin-Le Moal V, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clinical microbiology reviews 2006;19(2):315-37.

Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. International journal of food microbiology 2008;125(3):286-92.

Collado MC, Isolauri E, Salminen S. Specific probiotic strains and their combinations counteract adhesion of Enterobacter sakazakii to intestinal mucus. FEMS microbiology letters 2008;285(1):58-64.

Ruas-Madiedo P, Gueimonde M, Margolles A, de los Reyes-Gavilan CG, Salminen S. Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. Journal of food protection 2006;69(8):2011-5.

Lee J, Yang W, Hostetler A, Schultz N, Suckow MA, Stewart KL, et al. Characterization of the anti-inflammatory Lactobacillus reuteri BM36301 and its probiotic benefits on aged mice. BMC microbiology 2016;16:69.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut microbes 2016;7(3):189-200.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-44.

Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World journal of hepatology 2015;7(12):1708-17.

West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nature reviews Immunology 2015;15(10):615-29.

Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491(7423):254-8.

Jacouton E, Chain F, Sokol H, Langella P, Bermudez-Humaran LG. Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer. Frontiers in immunology 2017;8:1553.

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer cell 2009;15(2):103-13.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118(3):285-96.

Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Alimentary pharmacology & therapeutics 2000;14(12):1625-9.

Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Alimentary pharmacology & therapeutics 2001;15(2):163-9.

Armuzzi A, Cremonini F, Ojetti V, Bartolozzi F, Canducci F, Candelli M, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001;63(1):1-7.

Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Alimentary pharmacology & therapeutics 2002;16(9):1669-75.

Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. The American journal of gastroenterology 2002;97(11):2744-9.

Tursi A, Brandimarte G, Giorgetti GM, Modeo ME. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Medical science monitor : international medical journal of experimental and clinical research 2004;10(12):Cr662-6.

Sykora J, Valeckova K, Amlerova J, Siala K, Dedek P, Watkins S, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. Journal of clinical gastroenterology 2005;39(8):692-8.

Lionetti E, Miniello VL, Castellaneta SP, Magista AM, de Canio A, Maurogiovanni G, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Alimentary pharmacology & therapeutics 2006;24(10):1461-8.

Sheu BS, Cheng HC, Kao AW, Wang ST, Yang YJ, Yang HB, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. The American journal of clinical nutrition 2006;83(4):864-9.

Goldman CG, Barrado DA, Balcarce N, Rua EC, Oshiro M, Calcagno ML, et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition (Burbank, Los Angeles County, Calif) 2006;22(10):984-8.

Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Alimentary pharmacology & therapeutics 2005;21(10):1263-72.

Ojetti V, Bruno G, Ainora ME, Gigante G, Rizzo G, Roccarina D, et al. Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterology research and practice 2012;2012:740381.

Li Y. Adjuvant therapy for probiotics in patients with severe acute pancreatitis: an analysis of 14 cases [in Chinese]. Shijie Huaren Xiaohua Zazhi 2007;15:302-4.

Plaudis H, Pupelis G, Zeiza K, Boka V. Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study. Acta chirurgica Belgica 2012;112(2):131-8.

Cui LH, Wang XH, Peng LH, Yu L, Yang YS. [The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis]. Zhonghua wei zhong bing ji jiu yi xue 2013;25(4):224-8.




DOI: https://doi.org/10.22037/ghfbb.v11i4.1420

Creative Commons License
GHFBB by Gastroenterology and Liver Diseases Research Institute is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

PISSN: 2008-2258

EISSN: 2008-4234


•  

Privacy Policy | For Author | Online Submission | About | Contact

Copyright © 2018 Shahid Beheshti University of Medical Sciences. All rights reserved.